newratings.com  2 hrs ago  Comment 
FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) reported data from a Phase 2 study assessing simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 or LOXL2, in combination with gemcitabine for patients with earlier untreated...
StreetInsider.com  Sep 16  Comment 
52-Week High: Vimicro Int'l (Nasdaq: VIMC) $9.38. Vimicro Int'l is contining higher with strong volume. With the addition of over 30 percent on Tuesday, the stock is up over 125 percent in September alone. Positive comments from Needham &...
SeekingAlpha  Sep 16  Comment 
By Balanced Investing: Eli Lilly and Co. (NYSE:LLY), a drug manufacturer, has faced some challenges, with the patent expiration of its blockbuster drugs Cymbalta and Evista. The company's top line plunged 17% due to the 73% decline in Cymbalta's...
Jutia Group  Sep 16  Comment 
[PR Newswire] - INDIANAPOLIS, Sept. 16, 2014 /PRNewswire/ -- Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies 20 years in a row. In observance of the honor, Lilly is planning a series of...
StreetInsider.com  Sep 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Lilly+%26+Co.+%28LLY%29%2C+AstraZeneca++%28AZN%29+Enter+co-Development+Agreement+Covering+AZD3293/9834938.html for the full story.
Wall Street Journal  Sep 16  Comment 
AstraZeneca and Eli Lilly said they will jointly develop a risky experimental Alzheimer's drug that could rake in as much as $5 billion in annual sales, but that AstraZeneca has said stands just a 9% chance of success.
The Hindu Business Line  Sep 16  Comment 
SeekingAlpha  Sep 14  Comment 
By Sharon di Stefano: Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE:LLY) is no exception. Just recently, Lilly began selling Jardiance, a once-daily...
FiercePharma  Sep 12  Comment 
Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.
FiercePharma  Sep 12  Comment 
Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.
FierceBiotech  Sep 12  Comment 
Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize on oncology.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki